| Literature DB >> 16789744 |
Susanna Moore1, Holger Jaeschke, Gunnar Kleinau, Susanne Neumann, Stefano Costanzi, Jian-kang Jiang, John Childress, Bruce M Raaka, Anny Colson, Ralf Paschke, Gerd Krause, Craig J Thomas, Marvin C Gershengorn.
Abstract
The substituted thieno[2,3-d]pyrimidine 3 (Org 41841), a partial agonist for the luteinizing hormone/choriogonadotropin receptor (LHCGR) and the closely related thyroid-stimulating hormone receptor (TSHR), was fundamentally altered, and the resulting analogues were analyzed for their potencies, efficacies, and specificities at LHCGR and TSHR. Chemical modification of the parent compound combined with prior mutagenesis of TSHR provided compelling experimental evidence in support of computational models of 3 binding to TSHR and LHCGR within their transmembrane cores. Biochemical analysis of a specific modification to the chemical structure of 3 provides additional evidence of a H-bond between the ligand and a glutamate residue in transmembrane helix 3, which is conserved in both receptors. Several key interactions were surveyed to determine their respective biochemical roles in terms of both van der Waals dimensions and hydrogen bond capacity and the respective relationship to biological activity.Entities:
Mesh:
Substances:
Year: 2006 PMID: 16789744 PMCID: PMC2543117 DOI: 10.1021/jm060247s
Source DB: PubMed Journal: J Med Chem ISSN: 0022-2623 Impact factor: 7.446